Back to Back Issues Page
Pixium Vision Retinal Implant Research
March 30, 2022

Pixium Vision Retinal Implant Research

Pixium Vision announced FDA approval of an additional clinical trial site for the Prima System US feasibility study at Stanford Medicine in Standford, California. The two other US sites include the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania and Bascom Palmer Eye Institute in Miami, Florida.  There are 17 clinical trial sites in Europe including France, Germany, Spain, Italy, Netherlands and the United Kingdom.

What is the PRIMA Pixium Vision System? The Bionic Vision Restoration System, by Pixium Vision, received approval in the fall of 2017 from French regulators for the implant of a retinal chip in patients who have advanced dry macular degeneration . The chip is surgically placed in the subretinal space and works in conjunction with a headworn camera and a small data transmitter.

Artificial stimulation of degenerated photoreceptor cells allows for better communication between the eye and the brain. The first patient received the Pixium retinal implant and activation of the PRIMA system in France in January of 2018. As of August 30, 2018 all 5 French research participants were implanted with the retinal chip with the systems activated.

"We are pleased to have confirmed the durability of the better than expected outcome in our 6 month interim results in this 12 month data set. The fact that patients were able to not only re-establish light perception but also identify letters suggests that the PRIMA System may soon afford patients life changing improvements in quality of life," reports Lloyd Diamond, Chief Executive Officer of Pixium Vision.

Watch a short video and learn how this technology works to stimulate the retina in a new way to improve vision:

How Pixium's Bionic Vision Restoration System Works to Improve Vision

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page